menu
    • menu

    Company profile for Oxford Biotherapeutics

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OBT is a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate based therapies. OBT's commitment to the advancement of the field of cancer immunotherapy is focused on (i) the identification of novel immune check point targets, (ii) the optimisation of multiple antibody and bi-specific technologies for immuno-oncology and (iii) a broad clinical alliance for rapid testing in numerous ca...
    OBT is a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate based therapies. OBT's commitment to the advancement of the field of cancer immunotherapy is focused on (i) the identification of novel immune check point targets, (ii) the optimisation of multiple antibody and bi-specific technologies for immuno-oncology and (iii) a broad clinical alliance for rapid testing in numerous cancer types. Our product pipelines currently consist of (i) T-cell based IO therapies, namely check point modulators and (ii) NK cell based IO therapies, namely antibody dependent cell mediated toxicity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oxford Biotherapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    94a Innovation Drive Milton Park Abingdon OX14 4RZ
    Telephone
    Telephone
    +44 (0) 1235 861 770
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.oxfordbiotherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oxford Biotherapeutics Collaborates With Bristol Myers Squibb
    Oxford Biotherapeutics Collaborates With Bristol Myers Squibb

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270770/0/en/Oxford-BioTherapeutics-Enters-Strategic-Collaboration-with-Bristol-Myers-Squibb-to-Discover-and-Develop-Next-Generation-T-cell-Engagers-for-Solid-Tumours.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    Oxford Biotherapeutics Collaborates With GSK On Cancer Antibody
    Oxford Biotherapeutics Collaborates With GSK On Cancer Antibody

    10 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-10/oxford-biotherapeutics-enters-into-a-strategic-collaboration-with-gsk-to-discover-novel-targets-for-antibody-based-therapeutics-for-the-treatment-of-c

    PHARMIWEB
    10 Dec 2025
    Share Share
    Oxford BioTherapeutics Advances Third Oncology Drug
    Oxford BioTherapeutics Advances Third Oncology Drug

    03 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/03/3109680/0/en/Oxford-BioTherapeutics-Announces-Third-Oncology-Drug-Candidate-from-Boehringer-Ingelheim-Collaboration-Selected-to-Advance-into-IND-Enabling-Studies.html

    GLOBENEWSWIRE
    03 Jul 2025
    Share Share
    Roche doubles down on ADCs in $1B biobucks pact with Oxford Bio
    Roche doubles down on ADCs in $1B biobucks pact with Oxford Bio

    19 Mar 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/roche-continues-adc-dealmaking-spree-1b-pact-oxford-biotherapeutics

    FIERCE BIOTECH
    19 Mar 2025
    Share Share
    Boehringer Ingelheim Acquires Fourth Cancer Antibody License
    Boehringer Ingelheim Acquires Fourth Cancer Antibody License

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3007026/0/en/Boehringer-Ingelheim-Acquires-Fourth-License-for-the-Development-of-Novel-Antibody-Based-Cancer-Treatments-from-Oxford-BioTherapeutics.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share
    Oxford BioTherapeutics to Present at World ADC Conference 2024
    Oxford BioTherapeutics to Present at World ADC Conference 2024

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972530/0/en/Oxford-BioTherapeutics-to-Present-at-World-ADC-Conference-2024.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search